Literature DB >> 10770517

Absence of HHV-6 and HHV-7 in cerebrospinal fluid in relapsing-remitting multiple sclerosis.

C Taus1, E Pucci, E Cartechini, A Fié, G Giuliani, M Clementi, S Menzo.   

Abstract

OBJECTIVE: To contribute to clarifying the controversy on the association between Human Herpesviruses 6 and 7 (HHV-6, HHV-7) and multiple sclerosis (MS) studying patients with relapsing-remitting MS (RRMS) with or without evidence of disease activity (clinically or radiologically evaluated).
MATERIAL AND METHODS: In 25 RRMS patients, 7 suspected MS patients and 9 patients with other neurological diseases, the following parameters were analysed: i) antibody titers (IgM and IgG) against HHV-6 by indirect immunofluorescence both in serum and cerebrospinal fluid (CSF) samples; ii) PCR-detection of HHV-6 DNA and HHV-7 DNA in CSF and HHV-6 DNA in peripheral blood mononuclear cells (PBMCs). MS patients in remission underwent a gadolinium-enhanced magnetic resonance imaging in proximity of sample collections.
RESULTS: No viral DNA was found in any CSF sample, HHV-6 DNA frequency in PBMCs of MS patients and controls was not statistically different. Antibody titers against HHV-6 were comparable to those of the general population. Some 30.4% of MS patients were seronegative to HHV6.
CONCLUSION: Our data suggest that there is no relationship between HHV-6 or HHV-7 and MS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10770517     DOI: 10.1034/j.1600-0404.2000.101004224.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  18 in total

Review 1.  Human herpesvirus 6 infection as a trigger of multiple sclerosis.

Authors:  Konstantine I Voumvourakis; Dimitrios K Kitsos; Sotirios Tsiodras; George Petrikkos; Eleftherios Stamboulis
Journal:  Mayo Clin Proc       Date:  2010-10-06       Impact factor: 7.616

2.  Identification of human herpesviruses 1 to 8 in Tunisian multiple sclerosis patients and healthy blood donors.

Authors:  Nadia Ben Fredj; Antonella Rotola; Faten Nefzi; Saber Chebel; Roberta Rizzo; Elisabetta Caselli; Mahbouba Frih-Ayed; Dario Di Luca; Mahjoub Aouni
Journal:  J Neurovirol       Date:  2011-11-05       Impact factor: 2.643

3.  Prevalence of human Herpesviridae in cerebrospinal fluid of patients with multiple sclerosis and noninfectious neurological disease in the Netherlands.

Authors:  Gijsbert P van Nierop; Rogier Q Hintzen; Georges M G M Verjans
Journal:  J Neurovirol       Date:  2014-03-27       Impact factor: 2.643

4.  Molecular detection of human herpesvirus 7 DNA in cerebrospinal fluid from adult patients with neurological disorders.

Authors:  Íñigo Corral; Susana Sainz de la Maza; Mario Rodríguez; Michal-Maciej Kawiorski; María-José López-Martínez; Juan-Carlos Galán
Journal:  J Neurovirol       Date:  2018-03-13       Impact factor: 2.643

Review 5.  Insights into the immunopathogenesis of multiple sclerosis.

Authors:  Niels Hellings; Jef Raus; Piet Stinissen
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

6.  Detection of viral DNA and immune responses to the human herpesvirus 6 101-kilodalton virion protein in patients with multiple sclerosis and in controls.

Authors:  Maria V Tejada-Simon; Ying C Q Zang; Jian Hong; Victor M Rivera; James M Killian; Jingwu Z Zhang
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

Review 7.  Molecular methods for diagnosis of viral encephalitis.

Authors:  Roberta L Debiasi; Kenneth L Tyler
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

8.  Human herpesvirus type 6 indirectly enhances oligodendrocyte cell death.

Authors:  Hong Kong; Quinton Baerbig; Laine Duncan; Nick Shepel; Michael Mayne
Journal:  J Neurovirol       Date:  2003-10       Impact factor: 2.643

Review 9.  B cells in multiple sclerosis.

Authors:  Mark P Burgoon; Donald H Gilden; Gregory P Owens
Journal:  Front Biosci       Date:  2004-01-01

Review 10.  Viruses and multiple sclerosis.

Authors:  Jussi Oskari Virtanen; Steve Jacobson
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-08       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.